

Cite this: *RSC Adv.*, 2019, 9, 11718

Received 6th March 2019

Accepted 4th April 2019

DOI: 10.1039/c9ra01692a

rsc.li/rsc-advances

## Tunable chiral triazole-based halogen bond donors: assessment of donor strength in solution with nitrogen-containing acceptors†

Anna Peterson,<sup>‡ab</sup> Mikk Kaasik,<sup>‡b</sup> Andrus Metsala,<sup>b</sup> Ivar Järving,<sup>b</sup> Jasper Adamson<sup>\*a</sup> and Tõnis Kanger<sup>‡\*b</sup>

Strong halogen bond (XB) donors are needed for the activation of neutral substrates. We demonstrate that XB donor properties of iodo-triazoles can be significantly enhanced by quaternization in combination with varying the counterion and aromatic substituent, exemplified by association constants with quinuclidine as high as  $1.1 \times 10^4 \text{ M}^{-1}$ .

Halogen bond (XB) based applications utilize the attractive interaction between a Lewis acidic halogen atom and a Lewis base.<sup>1</sup> From the turn of the century numerous publications have focused on the use of XBs in the solid state<sup>2</sup> and more recently, in solution as well.<sup>3</sup> Among these applications the potential of XBs in catalysis<sup>4</sup> and anion recognition should be highlighted.<sup>5</sup> As shown by Huber *et al.* these fields can be closely associated, exemplified by halide abstraction reactions.<sup>6</sup>

Compared to anion recognition, the recognition of neutral species in solution has received less attention. Studies with neutral acceptors have a primary focus on the fundamental nature of halogen bonding, such as the influence of the solvent and the structure of the XB donor/acceptor on the strength of XBs.<sup>7</sup> Amines have usually been used as neutral acceptors in these studies for their high affinity towards XB donors. This property can potentially be utilized in the detection of biologically relevant amines by XBs.<sup>8</sup> From the synthetic point of view, the activation of neutral species through XBs is also a topic of high interest.<sup>9</sup> In general, compared to anions, neutral acceptors form weaker complexes with organic XB donors.<sup>1d,3c</sup> Therefore, XB donors with stronger halogen bonding ability should be used for the activation of neutral compounds. From a catalyst design perspective, information on the extent different structural fragments affect XB donor ability is of great value.

Recently, we became interested in applying XBs in asymmetric catalysis. Chiral 5-halo-1,2,3-triazoles are among the best

candidates of catalysts to achieve this goal.<sup>6b,9b,d</sup> The triazoles are readily available through a Cu-catalysed click reaction<sup>10</sup> and access to a broad range of alkynes with the possibility to quaternize the triazole core makes it feasible to enhance the donor ability of the triazole. In addition, the availability of many chiral azides offers wide opportunities for the design of new chiral XB donor systems.<sup>11</sup> We have shown the potential of these compounds to interact with various possible substrates and in enantiodiscrimination.<sup>12</sup> Due to relatively low affinity constants with thiourea acceptors, it was difficult to fully assess how structural modifications affect XB donors' binding ability. Therefore, a stronger XB acceptor has to be selected for this kind of analysis. Anionic species are known to give large affinity constants with halo-triazolium salts,<sup>13</sup> however, in these complexes charge attraction plays a key role in XB formation. We therefore chose quinuclidine,<sup>7d,h-k</sup> a neutral monodentate XB acceptor with a readily accessible lone pair, for screening of the effect of XB donor analogues (Fig. 1) on XB strength. Herein we describe the formation of complexes between triazole-based XB donors and quinuclidine in solution with emphasis on the influence of aromatic substituents and counterions on XB donor strength and investigate the XB donors' ability to discriminate between enantiomers of chiral imines and amines.

A collection of monodentate XB donors shown in Fig. 1 were synthesized (see ESI† for details). To determine the effect of structural changes, the triazolium salts were modified by introducing a perfluorophenyl or a *p*-nitrophenyl substituent instead of a phenyl substituent, changing the counterions and varying the halogen atoms. The XB donor ability of the synthesized compounds was determined through their respective association constants with quinuclidine in CDCl<sub>3</sub> based on <sup>1</sup>H NMR titration experiments. To evaluate the XB strength more accurately, the titration experiments were carried out in duplicate. The results are summarized in Table 1.

<sup>a</sup>Chemical Physics Laboratory, National Institute of Chemical Physics and Biophysics, Akadeemia tee 23, 12618, Tallinn, Estonia. E-mail: jasper.adamson@kbfi.ee

<sup>b</sup>Department of Chemistry and Biotechnology, School of Science, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. E-mail: tonis.kanger@taltech.ee

† Electronic supplementary information (ESI) available: Experimental procedures, titration experiments, computational information and copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra. See DOI: 10.1039/c9ra01692a

‡ These authors contribute equally to this work.






Fig. 1 XB donors and reference compound under study.

Table 1 Association constant  $K_a$  values<sup>a</sup> of the XB donor–quinuclidine pairs

Entry	XB donor	$K_a$ , M <sup>-1</sup>
1	1-OTf	57 ± 5
2	1-BARF	(1.23 ± 0.01) × 10 <sup>3</sup>
3	2-OTf	257 ± 12
4	2-BF <sub>4</sub>	284 ± 12
5	3-OTf	703 ± 6
6	3-BARF	(1.1 ± 0.3) × 10 <sup>4</sup>
7	4-OTf	<1
8	5-BARF	n.d. <sup>b</sup>
9	6-OTf	<1
10	7	2.0 ± 0.3

<sup>a</sup> Association constant  $K_a$  measured in CDCl<sub>3</sub> at 298 K and determined by fitting the <sup>1</sup>H NMR titration data to 1 : 1 binding isotherm of BindFit.<sup>15</sup> The given  $K_a$  and standard error are the calculated mean values of two parallel experiments. Full details given in the ESI†. <sup>b</sup>  $K_a$  could not be determined due to the instability of XB donor during the experiment.

To evaluate the influence of substituents of the aromatic ring that connects directly to the triazolium core on XB formation ability of the triazolium salts, a perfluorinated and a nitro-substituted derivative (3-OTf and 2-OTf, respectively) were compared with the unsubstituted phenyl derivative 1-OTf (Table 1, entries 1, 3 and 5). The affinity towards quinuclidine

decreases in the order of 3-OTf > 2-OTf > 1-OTf which corresponds to the decrease of the size of the  $\sigma$ -hole on the iodine atom.<sup>14</sup> The perfluorinated XB donor had more than twice as high affinity towards quinuclidine as the NO<sub>2</sub>-containing XB donor and over an order of magnitude higher affinity when compared to 1-OTf. The strong XB donating ability of perfluorinated XB donors is explained by its highly electronegative fluorine substituents that significantly increase the polarization of the C–X bond, therefore increasing the  $\sigma$ -hole.<sup>74,7i</sup> The electron-withdrawing nitro group in compound 2-OTf is similarly essential to enhance its XB donor ability, albeit less strongly compared to the more electron deficient perfluorophenyl group in 3-OTf. To determine that the changes in chemical shifts were indeed induced by halogen bonding, the nonhalogenated analogue 6-OTf was synthesized which expectedly did not interact favourably with quinuclidine (Table 1, entry 9).

The effects of anionic counterions were characterised based on triflate (1-OTf, 2-OTf, 3-OTf), tetrafluoroborate (2-BF<sub>4</sub>) and tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (1-BARF, 3-BARF) containing triazolium salts. Due to poor solubility, the comparison to 1-BF<sub>4</sub> could not be made. In general, the change of the counterion affected XB strength substantially in accordance with their coordination ability.<sup>16</sup> The less coordinating tetrafluoroborate containing triazolium salt 2-BF<sub>4</sub> showed higher affinity towards quinuclidine compared to the triflate containing salt 2-OTf (Table 1, entries 3 and 4). The introduction of the BARF counterion increased XB strength by more than one order of magnitude (Table 1, comparing entries 1 and 5 to entries 2 and 6). To the best of our knowledge, the obtained affinity constant between quinuclidine and 3-BARF is among the highest affinities reported so far for a neutral acceptor.<sup>36,7</sup> Usually XBs are stronger in apolar solvents than in more polar solvents<sup>7e,f,i</sup> and as a comparison, the association constant is only a magnitude smaller than that for the complex between quinuclidine and I<sub>2</sub> measured in heptane.<sup>7h</sup>

The strength of the XB is known to decrease based on the polarization of the halogen atom and the increase of electronegativity in the order of I > Br > Cl > F.<sup>1</sup> In our <sup>1</sup>H NMR titration study, the iodo-triazolium analogue (1-OTf) displayed moderate affinity towards quinuclidine whereas the corresponding bromine analogue (4-OTf) did not show any affinity towards quinuclidine altogether (Table 1, entry 7, also see ESI† for details). The absence of complex formation with the bromine derivative agrees with a similar outcome in our previous investigation.<sup>12</sup> In an attempt to obtain a complex containing a bromine atom as the donor, a bromo-triazolium salt 5-BARF with the strongly electronegative pentafluorophenyl substituent was synthesized. Nevertheless, the changes undertaken made the donor too labile and upon the titration experiment dehalogenation prevented the determination of the affinity constant (Table 1, entry 8, also see ESI† for details).

Quaternization of the triazole core has been critical to obtain compounds with sufficient XB donor ability.<sup>13b,17</sup> To ascertain the impact of charge in the triazole core, neutral perfluorinated triazole 7 was also titrated with quinuclidine. The obtained affinity constant is indeed very low. However, this result is of importance in its own right as there are only a few examples






Fig. 2 Chiral XB acceptors under study.

describing complex formation in solution between a neutral halo-triazole and a neutral acceptor.<sup>18</sup> The difference between the neutral XB donor (7) and its charged derivative (3-OTf) is more than two orders of magnitude (Table 1, entries 5 and 10). However, if the counterion acts as an acceptor and competes with quinuclidine for XB formation, triazole 7 should be compared to 3-BARF, which has the less coordinating BARF counterion and therefore provides a better representation for a “naked” cationic backbone. In this case, the difference in binding ability of four orders of magnitude was observed (Table 1, entries 6 and 10).

Furthermore, <sup>1</sup>H NMR titrations measurements were performed using both enantiomers of chiral imine 8 and amine 9 (Fig. 2) to determine whether the XB donors are able to selectively interact with chiral substances. For these experiments, 3-BARF was chosen as the donor due to the highest binding affinity towards quinuclidine. The XB donor showed no preference towards either enantiomer of the selected acceptors since no differences between the two enantiomers  $K_a$  values were observed in either case (Table 2, entries 1 and 2; entries 3 and 4). Nevertheless, the affinity constant between amine 9 and 3-BARF is considerably higher compared to the only reported example, where the XB strength between an organic XB donor and secondary amine was measured.<sup>7j</sup> The affinity constant between perfluorohexyl iodide and piperidine was <1 in all three solvents used in that study. The difference compared to the binding strength of quinuclidine can partly be explained by the fact that cyclic amines are better acceptors than acyclic amines.<sup>7j</sup>

Calculations were performed on the CAM/B3LYP<sup>19</sup> level of theory using DEF2TZVP basis set<sup>20</sup> to model the interaction between both enantiomers of amine 9 and 3-OTf. The calculated complexes in the vacuum and in CHCl<sub>3</sub> had similar energy values (see ESI† for details). The substituents on the triazole core are most likely not sufficiently bulky to differentiate between the two enantiomers through steric repulsion or by

Table 2 Association constant  $K_a$  values<sup>a</sup> of the chiral acceptor and 3-BARF pairs

Entry	XB acceptor	$K_a$ , M <sup>-1</sup>
1	(R)-8	6.1 ± 0.7
2	(S)-8	6.0 ± 0.8
3	(R)-9	94 ± 7
4	(S)-9	91 ± 5

<sup>a</sup> Association constant  $K_a$  measured in CDCl<sub>3</sub> at 298 K and determined by fitting the <sup>1</sup>H NMR titration data to 1 : 1 binding isotherm of BindFit.<sup>15</sup> The given  $K_a$  and standard error are the calculated mean values of two parallel experiments. Full details given in the ESI.




Fig. 3 Calculated minimum energy complexes formed through a XB between donor 3-OTf and (S)- or (R)-enantiomer of amine 9 (A and B respectively).

other noncovalent interactions (Fig. 3). This could also explain our previously obtained results of enantiodiscrimination experiments, where Takemoto's catalyst<sup>21</sup> was used as an acceptor and that suggest that both hydrogen and halogen bonding interactions influenced the binding of enantiomers.<sup>12</sup> Therefore, a more beneficial approach would be to use multi-dentate or bifunctional XB donors that form more rigid complexes. For example, Beer *et al.* has shown that chiral bidentate XB donors that contain at least two halo-triazole cores are suitable for differentiating between enantiomers.<sup>13a,22</sup>

In conclusion, we have once again shown the pivotal role of charge on XB donor strength. In addition, by changing the aromatic substituent and the counterion, the XB donor properties of triazole-based donors can be enhanced even further. This is exemplified by the fact that the donors form complexes with quinuclidine with association constants covering almost four orders of magnitude. To the best of our knowledge, the reported association constants are comparable to the largest described between an amine and an organic XB donor in solution. Enantiodiscrimination of acceptors 8 and 9 by the most powerful donor 3-BARF was not observed. However, information obtained during this study can aid to move towards more selective donors.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The present study was supported by Estonian Ministry of Education and Research (Grant No. IUT 19-32, IUT 19-9, IUT 23-7, PUT1468 and PRG399) and the Centre of Excellence in Molecular Cell Engineering 2014-2020.4.01.15-0013 as well as the Centre of Excellence TK134. We thank Dr Aleksander-Mati Müürisepp for the IR spectra, Dr Kadri Kriis and Mrs Egle Rinaldo for their help on the synthesis.

## Notes and references

- (a) Á. M. Montaña, *ChemistrySelect*, 2017, 2, 9094; (b) G. Cavallo, P. Metrangolo, R. Milani, T. Pilati, A. Priimagi, G. Resnati and G. Terraneo, *Chem. Rev.*, 2016, 116, 2478; (c) H. Wang, W. Wang and W. J. Jin, *Chem. Rev.*, 2016, 116,



- 5072; (d) L. C. Gilday, S. W. Robinson, T. A. Barendt, M. J. Langton, B. R. Mullaney and P. D. Beer, *Chem. Rev.*, 2015, **115**, 7118.
- 2 (a) J.-C. Christopherson, F. Topić, C. J. Barrett and T. Frisčić, *Cryst. Growth Des.*, 2018, **18**, 1245; (b) B. Li, S.-Q. Zang, L.-Y. Wang and T. C. W. Mak, *Coord. Chem. Rev.*, 2016, **308**, 1; (c) G. Berger, J. Soubhy and F. Meyer, *Polym. Chem.*, 2015, **6**, 3559; (d) A. Mukherjee, S. Tothadi and G. R. Desiraju, *Acc. Chem. Res.*, 2014, **47**, 2514; (e) R. W. Troff, T. Mäkelä, F. Topić, A. Valkonen, K. Raatikainen and K. Rissanen, *Eur. J. Org. Chem.*, 2013, **2013**, 1617; (f) K. Rissanen, *CrystEngComm*, 2008, **10**, 1107.
- 3 (a) A. V. Jentzsch, *Pure Appl. Chem.*, 2015, **87**, 15; (b) A.-C. C. Carlsson, A. X. Veiga and M. Erdélyi, *Top. Curr. Chem.*, 2014, **359**, 49; (c) T. M. Beale, M. G. Chudzinski, M. G. Sarwar and M. S. Taylor, *Chem. Soc. Rev.*, 2013, **42**, 1667.
- 4 (a) M. Breugst and D. von der Heiden, *Chem.–Eur. J.*, 2018, **24**, 9187; (b) D. Bulfield and S. M. Huber, *Chem.–Eur. J.*, 2016, **22**, 14434; (c) S. Schindler and S. M. Huber, *Top. Curr. Chem.*, 2014, **359**, 167.
- 5 (a) R. Tepper and U. S. Schubert, *Angew. Chem., Int. Ed.*, 2018, **57**, 6004; (b) A. Brown and P. D. Beer, *Chem. Commun.*, 2016, **52**, 8645.
- 6 (a) F. Heinen, E. Engelage, A. Dreger, R. Weiss and S. M. Huber, *Angew. Chem., Int. Ed.*, 2018, **57**, 3830; (b) A. Dreger, E. Engelage, B. Mallick, P. D. Beer and S. M. Huber, *Chem. Commun.*, 2018, **54**, 4013; (c) S. H. Jungbauer and S. M. Huber, *J. Am. Chem. Soc.*, 2015, **137**, 12110; (d) F. Kniep, S. H. Jungbauer, Q. Zhang, S. M. Walter, S. Schindler, I. Schnapperelle, E. Herdtweck and S. M. Huber, *Angew. Chem., Int. Ed.*, 2013, **52**, 7028; (e) F. Kniep, L. Rout, S. M. Walter, H. K. V. Bensch, S. H. Jungbauer, E. Herdtweck and S. M. Huber, *Chem. Commun.*, 2012, **48**, 9299.
- 7 (a) A. M. S. Riel, M. J. Jessop, D. A. Decato, C. J. Massena, V. R. Nascimento and O. B. Berryman, *Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.*, 2017, **73**, 203; (b) G. Ciancaleoni, A. Macchioni, L. Rocchigiani and C. Zuccaccia, *RSC Adv.*, 2016, **6**, 80604; (c) R. Puttreddy, O. Jurčák, S. Bhowmik, T. Mäkelä and K. Rissanen, *Chem. Commun.*, 2016, **52**, 2338; (d) O. Dumele, D. Wu, N. Trapp, N. Goroff and F. Diederich, *Org. Lett.*, 2014, **16**, 4722; (e) S. H. Jungbauer, D. Bulfield, F. Kniep, C. W. Lehmann, E. Herdtweck and S. M. Huber, *J. Am. Chem. Soc.*, 2014, **136**, 16740; (f) C. C. Robertson, R. N. Perutz, L. Brammer and C. A. Hunter, *Chem. Sci.*, 2014, **5**, 4179; (g) B. Hawthorne, H. Fan-Hagenstein, E. Wood, J. Smith and T. Hanks, *Int. J. Spectrosc.*, 2013, **2013**, 1; (h) C. Laurence, J. Graton, M. Berthelot and M. J. El Ghomari, *Chem.–Eur. J.*, 2011, **17**, 10431; (i) M. G. Sarwar, B. Dragisic, L. J. Salsberg, C. Gouliaras and M. S. Taylor, *J. Am. Chem. Soc.*, 2010, **132**, 1646; (j) R. Cabot and C. A. Hunter, *Chem. Commun.*, 2009, 2005; (k) P. Metrangolo, W. Panzeri, F. Recupero and G. Resnati, *J. Fluorine Chem.*, 2002, **114**, 27.
- 8 X. X. Zhang, J. S. Bradshaw and R. M. Izatt, *Chem. Rev.*, 1997, **97**, 3313.
- 9 (a) G. Bergamaschi, L. Lascialfari, A. Pizzi, M. I. M. Espinoza, N. Demitri, A. Milani, A. Gori and P. Metrangolo, *Chem. Commun.*, 2018, **54**, 10718; (b) R. Haraguchi, S. Hoshino, M. Sakai, S. Tanazawa, Y. Morita, T. Komatsu and S. Fukuzawa, *Chem. Commun.*, 2018, **54**, 10320; (c) J.-P. Gliese, S. H. Jungbauer and S. M. Huber, *Chem. Commun.*, 2017, **53**, 12052; (d) D. von der Heiden, E. Detmar, R. Kuchta and M. Breugst, *Synlett*, 2017, **28**, 1307.
- 10 (a) J. M. Pérez, P. Crosbie, S. Lal and S. Díez-González, *ChemCatChem*, 2016, **8**, 2222; (b) J. García-Álvarez, J. Díez and J. Gimeno, *Green Chem.*, 2010, **12**, 2127; (c) J. E. Hein, J. C. Tripp, L. B. Krasnova, K. B. Sharpless and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2009, **48**, 8018; (d) B. H. M. Kuipers, G. C. T. Dijkmans, S. Groothuys, P. J. L. M. Quaedflieg, R. H. Blaauw, F. L. van Delft and F. P. J. T. Rutjes, *Synlett*, 2005, 3059.
- 11 M. Kaasik, S. Kaabel, K. Kriis, I. Järving and T. Kanger, *Synthesis*, 2019, DOI: 10.1055/s-0037-1610864.
- 12 M. Kaasik, S. Kaabel, K. Kriis, I. Järving, R. Aav, K. Rissanen and T. Kanger, *Chem.–Eur. J.*, 2017, **23**, 7337.
- 13 (a) J. Y. C. Lim, I. Marques, V. Félix and P. D. Beer, *Chem. Commun.*, 2018, **54**, 10851; (b) R. Tepper, B. Schulze, M. Jäger, C. Friebe, D. H. Scharf, H. Görls and U. S. Schubert, *J. Org. Chem.*, 2015, **80**, 3139.
- 14 M. Kaasik, A. Metsala, S. Kaabel, K. Kriis, I. Järving and T. Kanger, *J. Org. Chem.*, 2019, **84**, 4294–4303.
- 15 Freely available at <http://www.supramolecular.org> (accessed February 22, 2019).
- 16 (a) I. Krossing and I. Raabe, *Angew. Chem., Int. Ed.*, 2004, **43**, 2066; (b) S. H. Strauss, *Chem. Rev.*, 1993, **93**, 927.
- 17 (a) B. Nepal and S. Scheiner, *Chem.–Eur. J.*, 2015, **21**, 13330; (b) B. Nepal and S. Scheiner, *J. Phys. Chem. A*, 2015, **119**, 13064.
- 18 L. Maugeri, J. Asencio-Hernández, T. Lébl, D. B. Cordes, A. M. Z. Slawin, M. Delsuc and D. Philp, *Chem. Sci.*, 2016, **7**, 6422.
- 19 T. Yanai, D. Tew and N. Handy, *Chem. Phys. Lett.*, 2004, **393**, 51.
- 20 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297.
- 21 T. Okino, Y. Hoashi and Y. Takemoto, *J. Am. Chem. Soc.*, 2003, **125**, 12672.
- 22 (a) A. Borisso, J. Y. C. Lim, A. Brown, K. E. Christensen, A. L. Thompson, M. D. Smith and P. D. Beer, *Chem. Commun.*, 2017, **53**, 2483; (b) J. Y. C. Lim, I. Marques, L. Ferreira, V. Félix and P. D. Beer, *Chem. Commun.*, 2016, **52**, 5527.

